Urinary Tract Stones

Primary Care - Clinics in Office Practice

Volumn 37, Issue 3, 2010, Pages 565-581

  Schade, George R ^a   Faerber, Gary J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Lithotripsy; Medical expulsive therapy; Nephrolithiasis; Ureteral calculi; Urinary tract stones; Urolithiasis

Indexed keywords

ALLOPURINOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM OXALATE; CAPTOPRIL; CITRATE POTASSIUM; CYSTEINE; EPHEDRINE; HYDROCHLOROTHIAZIDE; INDINAVIR; KETOROLAC; MAGNESIUM; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PHOSPHATE; STRUVITE; TAMSULOSIN; TRIAMTERENE; URIC ACID;

ABDOMINAL RADIOGRAPHY; BLEEDING; CALCIUM OXALATE STONE; CALCIUM STONE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DOSE RESPONSE; DRUG DOSE TITRATION; ECHOGRAPHY; EXTRACORPOREAL LITHOTRIPSY; HUMAN; HYPERCALCIURIA; HYPERPARATHYROIDISM; INTESTINE INJURY; INTRAVENOUS PYELOGRAPHY; NEPHROLITHIASIS; NUTRITIONAL ASSESSMENT; ORAL REHYDRATION THERAPY; ORGAN INJURY; PATHOPHYSIOLOGY; PATIENT CARE; PERCUTANEOUS NEPHROLITHOTOMY; POSTOPERATIVE HEMORRHAGE; PRECIPITATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SEX DIFFERENCE; TISSUE INJURY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UNITED STATES; URETER INJURY; URETER STONE; URETER STRICTURE; URETEROSCOPY; URIC ACID STONE; URINARY TRACT OBSTRUCTION; UROLITHIASIS;

EID: 77955494848     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2010.05.003     Document Type: Review

References (75)

1. Stamatelou K.K., Francis M.E., Jones C.A., et al. Time trends in reported prevalence of kidney stones in the United States. Kidney Int 2003, 63:1817-1823.
2. Pearle M.S., Calhoun E.A., Curhan G.C., et al. Urologic diseases in America project: urolithiasis. J Urol 2005, 173:848-857.
3. Pak C.Y. Should patients with single renal stone occurrence undergo diagnostic evaluation?. J Urol 1982, 127:855-857.
4. Johnson C.M., Wilson D.M., O'Fallon W.M., et al. Renal stone epidemiology: a 25 year study in Rochester, Minnesota. Kidney Int 1979, 16:624-631.
5. Scales C.D., Curtis L.H., Norris R.D., et al. Changing gender prevalence of stone disease. J Urol 2007, 177:979-982.
6. Rous S.N. A review of 171 consecutive patients with urinary lithiasis. J Urol 1981, 126:376-379.
7. Sarmina I., Spirnak J.P., Resnick M.I. Urinary lithiasis in the black population: an epidemiologic study and review of the literature. J Urol 1987, 138:14-17.
8. Soucie J.M., Thun M.J., Coates R.J., et al. Demographic and geographic variability of kidney stones in the United States. Kidney Int 1977, 46:893-899.
9. Maloney M.E., Springhart W.P., Ekerou W.O., et al. Ethnic background has minimal impact on the etiology of nephrolithiasis. J Urol 2005, 173:2001-2004.
10. Prince C.L., Scardino P.L. A statistical analysis of ureteral calculi. J Urol 1960, 83:561-565.
11. Schwartz B., Schenkman N., Bruce J., et al. Calcium nephrolithiasis: effect of water hardness on urinary electrolytes. Urology 2002, 60:23-27.
12. van Aswegen C.H., du Plessis D.J. Pathogenesis of kidney stones. Med Hypotheses 1991, 36:368-370.
13. Stoller M.L., Meng M.V., Abrahams H.M., et al. The primary stone event: a new hypothesis involving a vascular etiology. J Urol 2004, 171:1920-1924.
14. Matlaga B.R., Coe F.L., Evan A.P., et al. The role of Randall's plaques in the pathogenesis of calcium stones. J Urol 2007, 177:31-38.
15. Pak C.Y., Peterson R. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate. Arch Intern Med 1986, 146:863-867.
16. Nicar M.J., Hill K., Pak C.Y. Inhibition by citrate of spontaneous precipitation of calcium oxalate in vitro. J Bone Miner Res 1987, 2:215-220.
17. Nakagawa Y., Ahmed M., Hall S.L., et al. Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gamma-carboxyglutamic acid. J Clin Invest 1987, 79:1782-1787.
18. Asplin J.R., Arsenault D., Parks J.H., et al. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int 1998, 53:194-199.
19. Taylor E.N., Stampfer M.J., Curhan G.C. Obesity, weight gain, and the risk of kidney stones. JAMA 2005, 293:455-462.
20. Seiner R., Glatz S., Nicolay C., et al. The role of overweight and obesity in calcium oxalate stone formation. Obes Res 2004, 12:106-113.
21. Kaufman D.W., Kelly J.P., Curhan G.C., et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 2008, 19:1197-1203.
22. Troxel S.A., Sidhu H., Kaul P., et al. Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate. J Endourol 2003, 17:173-176.
23. Griffith D.P., Osborne C.A. Infection (urease) stones. Miner Electrolyte Metab 1987, 13:278-285.
24. Faerber G.J. Pediatric urolithiasis. Curr Opin Urol 2001, 11:385-389.
25. Ettinger B., Oldroyd N.O., Sorger F. Triamterene nephrolithiasis. JAMA 1980, 244:2443-2445.
26. Colistro R., Torreggiani W.C., Lyburn I.D. Unenhanced helical CT in the investigation of acute flank pain. Clin Radiol 2002, 57:435-441.
27. Sodickson A., Baeyens P.F., Andriole K.P., et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology 2009, 25:175-184.
28. Coll D.M., Varanelli M.J., Sith R.C. Relationship of spontaneous passage of ureteral calculi to stone size and location as revealed by unenhanced helical CT. AJR Am J Roentgenol 2002, 178:101-103.
29. Segura J.W., Preminger G.M., Assimos D.G., et al. Ureteral stones clinical guidelines panel summary report on the management of ureteral calculi. J Urol 1997, 158:1915-1921.
30. Miller O.F., Kane C.J. Time to stone passage for observed ureteral calculi: a guide for patient education. J Urol 1999, 162:688-691.
31. Holdgate A., Pollock T. Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic. BMJ 2004, 328:1401-1404.
32. Hollingsworth J., Rogers M., Kaufman S., et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet 2006, 368:1171-1179.
33. Agrawal M., Naja V., Singh S., et al. Is there an adjunctive role of tamsulosin to extracorporeal shockwave lithotripsy for upper ureteral stones: results of an open label randomized nonplacebo controlled trial. Urology 2009, 74:989-992.
34. Dellabella M., Milanese G., Mussonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J Urol 2006, 174:167-172.
35. Porpiglia F., Ghignone G., Fiori C., et al. Nifedipine versus tamsulosin for the management of lower ureteral stones. J Urol 2004, 172:568-571.
36. Bensalah K., Pearle M., Lotan Y. Cost-effectiveness of medical expulsive therapy using alpha-blockers for the treatment of distal ureteral stones. Eur Urol 2008, 53:411-419.
37. Strohmaier W.L. Course of calcium stone disease without treatment. What can we expect. Eur Urol 2000, 37:339-344.
38. Stoller M.L. Urinary stone disease. Smith's general urology 1995, 27-34. Appleton and Lange, Norwalk (CT). 14th edition. E.A. Tanagho, J.W. McAnich (Eds.).
39. Esen T., Marshall V.R., Rao N., et al. Medical management of urolithiasis. Stone disease 2003, 133-149. Health Publications, Paris. J.W. Segura, P. Conort, S. Khoury (Eds.).
40. Curhan G.C., Willett W.C., Rimm E.B., et al. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993, 328:833-838.
41. Curhan G.C., Willett W.C., Knight E.L., et al. Dietary factors and the risk of incident kidney stones in younger women: Nurses Health Study II. Arch Intern Med 2004, 163:885-891.
42. Matlaga B.R., Shore A.D., Magnuson T., et al. Effect of gastric bypass surgery on kidney stone disease. J Urol 2009, 181:2573-2577.
43. Traxer O., Huet B., Poindexter J., et al. Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 2003, 170:397-401.
44. Gettman M.T., Ogan K., Brinkley L.J., et al. Effect of cranberry juice consumption on urinary stone risk factors. J Urol 2005, 174:590-594.
45. Park A.M., Storm D.W., Fulmer B.R., et al. A prospective study of risk factors for nephrolithiasis after Roux-en-Y gastric bypass surgery. J Urol 2009, 182:2334-2339.
46. Sinha M.K., Collazo-Clavell M.L., Rule A., et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int 2007, 72:100-107.
47. Semins M.J., Matlaga B.R., Shore A.D., et al. The effect of gastric banding on kidney stone disease. Urology 2009, 74:746-749.
48. Penniston K.L., Kaplon D.M., Gould J.C., et al. Gastric band placement for obesity is not associated with increased urinary risk of urolithiasis compared to bypass. J Urol 2009, 182:2340-2346.
49. Pace K.T., Ghiculete D., Harju M., et al. Shock wave lithotripsy at 60 or 120 shocks per minute: a randomized, double blind study. J Urol 2005, 174:595-599.
50. Zhou Y., Cocks F.H., Preminger G.N., et al. Innovations in shock wave lithotripsy technology: updates in experimental studies. J Urol 2004, 172:1892-1898.
51. Kupeli B., Irkilata L., Gürocak S., et al. Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy?. Urology 2004, 64:1111-1115.
52. Gravina G.L., Costa A.M., Ronchi P., et al. Tamsulosin treatment increases clinical success rate of single extra corporeal shock wave lithotripsy of renal stones. Urology 2005, 66:24-28.
53. Porpiglia F., Destefanis P., Fiori, et al. Role of adjunctive medical therapy with nifedipine and deflazacort after extracorporeal shock wave lithotripsy of ureteral stones. Urology 2002, 59:835-838.
54. Hollingsworth J.M., Rogers M.A., Kaufman S.R., et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet 2006, 368:1138-1139.
55. Weizer A., Preminger G.M. Shock wave lithotripsy: current technology and evolving concepts. AUA Updates 2005, 24(36):314-323.
56. Bierkens A.F., Hendrikx A.J., Lemmens W.A., et al. Extracorporeal shock wave lithotripsy for large calculi: the role of ureteral stents. A randomized trial. J Urol 1991, 145:699-702.
57. Prior J.L., Jenkins A.D. Use of double pigtail stents in extracorporeal shock wave lithotripsy. J Urol 1990, 143:475-478.
58. Chandhoke P.S., Barqawi A.Z., Wernecke C., et al. A randomized outcomes trial of ureteral stents for extracorporeal shock wave lithotripsy of solitary kidney or proximal ureteral stones. J Urol 2002, 167:1981-1983.
59. Knapp P.M., Kulb T.B., Lingeman J.E., et al. Extracorporeal shock wave lithotripsy induced perirenal hematomas. J Urol 1988, 139:700-703.
60. Dhar N.B., Thornton J., Karafa M.T., et al. A multivariate analysis of risk factors associated with subcapsular hematoma formation following electromagnetic shock wave lithotripsy. J Urol 2004, 172:2271-2274.
61. Kostakopoulos A., Stavropoulos N.J., Macrychoritis C., et al. Subcapsular hematoma due to ESWL: risk factors. A study of 4,247 patients. Urol Int 1995, 55:21-24.
62. Newman L.H., Saltzman B. Identifying risk factors in development of clinically significant post shock wave lithotripsy subcapsular hematomas. Urology 1991, 38:35-38.
63. Coptcoat M.J., Webb D.R., Kellett M.J., et al. The complications of extracorporeal shock wave lithotripsy: management and prevention. Br J Urol 1986, 58:578.
64. Krambeck A.E., Gettman M.T., Rohlinger A.L., et al. Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. J Urol 2006, 175:1742-1747.
65. Watterson J.D., Girvan A.R., Cook A.J., et al. Safety and efficacy of holmium: YAG laser lithotripsy in patients with bleeding diathesis. J Urol 2002, 168:442-445.
66. Hollenbeck B.K., Schuster T.G., Faerber G.J., et al. Routine placement of ureteral stents is unnecessary after ureteroscopy for urinary calculi. Urology 2001, 57(4):639-643.
67. Srivastava A., Gupta R., Kumar A., et al. Routine stenting after ureteroscopy for distal ureteral calculi is unnecessary: results of a randomized clinical trial. J Endourol 2003, 17(10):871-874.
68. Byrne R.R., Auge B.K., Kourambas, et al. Routine ureteral stenting is not necessary after ureteroscopy and ureteropyeloscopy: a randomized trial. J Endourol 2002, 16(1):9-13.
69. Borboroglu P.G., Amling C.L., Schenkman N.S., et al. Ureteral stenting after ureteroscopy for distal ureteral calculi: a multi institutional prospective randomized controlled study assessing pain, outcomes and complications. J Urol 2001, 166(5):1651-1657.
70. Johnson D.B., Pearle M.S. Complications of ureteroscopy. Urol Clin North Am 2004, 31:157-171.
71. Stoller M.L., Wolf J.S. Endoscopic ureteral injuries. Traumatic and reconstructive urology 1996, 199-211. WB Saunders, Philadelphia. J.W. McAninch (Ed.).
72. Shah H.N., Kausik V.B., Hedge S.S., et al. Tubeless percutaneous nephrolithotomy: a prospective feasibility study and review of previous reports. BJU Int 2005, 96:879-883.
73. Faerber G.J., Gow M. Percutaneous nephrolithotripsy in morbidly obese patients. Tech Urol 1997, 3:2-7.
74. Kumar A., Banerjee G.K., Tewari A., et al. Isolated duodenal injury during relook percutaneous nephrolithotomy. Br J Urol 1994, 74(3):382-383.
75. Begun F.P., Jacobs S.C., Lawson R.K. Small bowel perforation during percutaneous nephrolithotomy. J Endourol 1989, 3:81.